Margarida Maia, PhD,  science writer—

Blood levels of globulins — a group of proteins that includes antibodies — when ANCA-associated vasculitis (AAV) is diagnosed can help in forecasting the risk of a patient dying of any cause, a large data study from Korea suggests. “The present study is the first to demonstrate that [total…

Treatment with Tavneos (avacopan) results in significant and clinically meaningful improvements in health-related quality of life (HRQoL) for people with ANCA-associated vasculitis (AAV), according to findings from the Phase 3 ADVOCATE clinical trial. “The ADVOCATE study is, to our knowledge, the first trial in patients with ANCA-associated vasculitis…

Dosing has begun in a Phase 2 clinical trial of imlifidase, an  antibody-cleaving therapy, in people with ANCA-associated vasculitis (AAV) who have or are at risk of disease-associated acute respiratory distress syndrome (ARDS), Hansa Biopharma, the therapy’s developer, announced. ARDS, a severe complication of AAV, occurs…

Developing pulmonary hypertension (PH), which occurs when pressure in the blood vessels that supply the lungs becomes too high, more than triples the mortality risk among people with ANCA-associated vasculitis (AAV), a study finds. PH may be relatively more common in AAV patients than understood, occurring in about…

Nearly half of eosinophilic granulomatosis with polyangiitis (EGPA) patients are able to stop taking glucocorticoids after a median of nine months on Nucala (mepolizumab), a small study in Japan suggests. This was true even for those with severe symptoms of this rare type of ANCA-associated vasculitis (AAV),…

Immunosuppressants may help prevent subglottic stenosis — a condition wherein part of the windpipe becomes tight — from returning in people with a type of ANCA-related vasculitis called granulomatosis with polyangiitis (GPA), a small Italian study suggests. The study, “Role of systemic immunosuppression on subglottic stenosis in granulomatosis…

A blood marker, called C-reactive protein to albumin ratio (CAR), may predict and help monitor disease activity in people with ANCA-associated vasculitis (AAV), according to a small study in Turkey. This is important in clinical practice because “close monitoring, early recognition, and timely treatment of disease activity may limit…

Two types of self-reactive antibodies, called anti-HMGB1 and anti-moesin antibodies, are present at significantly higher levels in the blood of ANCA-associated vasculitis (AAV) patients relative to healthy people and those with other autoimmune diseases, a study shows. The levels of these antibodies are also linked to how AAV manifested…

About 1 in 10 people with ANCA-associated vasculitis (AAV) failed to achieve complete remission at three months after starting induction treatment with rituximab, according to a small study in France. Poor responders were more likely to have symptoms in a specific area of the body — a localized form…

Argenx is planning to launch a proof-of-concept clinical trial later this year to test its therapy efgartigimod, approved to treat another autoimmune disease, in people with ANCA-associated vasculitis (AAV). Data from proof-of-concept studies can help companies and their researchers decide whether to develop a medicine for a specific…